1. Home
  2. MIRM vs AGYS Comparison

MIRM vs AGYS Comparison

Compare MIRM & AGYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • AGYS
  • Stock Information
  • Founded
  • MIRM 2018
  • AGYS 1963
  • Country
  • MIRM United States
  • AGYS United States
  • Employees
  • MIRM N/A
  • AGYS N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • AGYS EDP Services
  • Sector
  • MIRM Health Care
  • AGYS Technology
  • Exchange
  • MIRM Nasdaq
  • AGYS Nasdaq
  • Market Cap
  • MIRM 1.9B
  • AGYS 2.0B
  • IPO Year
  • MIRM 2019
  • AGYS N/A
  • Fundamental
  • Price
  • MIRM $44.27
  • AGYS $80.97
  • Analyst Decision
  • MIRM Strong Buy
  • AGYS Strong Buy
  • Analyst Count
  • MIRM 10
  • AGYS 5
  • Target Price
  • MIRM $60.80
  • AGYS $124.00
  • AVG Volume (30 Days)
  • MIRM 425.9K
  • AGYS 198.3K
  • Earning Date
  • MIRM 05-07-2025
  • AGYS 05-19-2025
  • Dividend Yield
  • MIRM N/A
  • AGYS N/A
  • EPS Growth
  • MIRM N/A
  • AGYS N/A
  • EPS
  • MIRM N/A
  • AGYS 0.79
  • Revenue
  • MIRM $379,251,000.00
  • AGYS $263,572,999.00
  • Revenue This Year
  • MIRM $29.51
  • AGYS $17.18
  • Revenue Next Year
  • MIRM $20.27
  • AGYS $16.88
  • P/E Ratio
  • MIRM N/A
  • AGYS $102.91
  • Revenue Growth
  • MIRM 69.31
  • AGYS 15.53
  • 52 Week Low
  • MIRM $23.83
  • AGYS $63.71
  • 52 Week High
  • MIRM $54.23
  • AGYS $142.64
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.45
  • AGYS 68.14
  • Support Level
  • MIRM $40.00
  • AGYS $74.40
  • Resistance Level
  • MIRM $47.43
  • AGYS $77.17
  • Average True Range (ATR)
  • MIRM 2.07
  • AGYS 2.48
  • MACD
  • MIRM 0.54
  • AGYS 1.20
  • Stochastic Oscillator
  • MIRM 65.27
  • AGYS 96.54

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About AGYS Agilysys Inc.

Agilysys Inc has been a leader in hospitality software, delivering innovative cloud-native SaaS and on-premise solutions for hotels, resorts and cruise lines, casinos, corporate food service management, restaurants, universities, stadiums, and healthcare. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. Agilysys also is known for its world-class customer-centric service.

Share on Social Networks: